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Abstract
Over the past two decades, it has become increasingly apparent that Alzheimer’s disease neuropathology is
characterized by activated microglia (brain resident macrophages) as well as the classic features of amyloid plaques
and neurofibrillary tangles. The intricacy of microglial biology has also become apparent, leading to a heightened
research interest in this particular cell type. Over the years a number of different microglial cell culturing techniques
have been developed to study either primary mammalian microglia, or immortalized cell lines. Each microglial
system has advantages and disadvantages and should be selected for its appropriateness in a particular research
context. This review summarizes several of the most common microglial cell culture systems currently being
employed in Alzheimer’s research including primary microglia; BV2 and N9 retroviral immortalized microglia; human
immortalized microglia (HMO6); and spontaneously immortalized rodent microglial lines (EOC lines and HAPI cells).
Particularities of cell culture requirements and characteristics of microglial behavior, especially in response to
applied inflammogen stimuli, are compared and discussed across these cell types.
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Introduction
Microglia are the resident phagocytes and innate im-
mune cells of the brain. Over the past few decades, there
has been an increased interest in microglia, as many
investigators have recognized the importance of this cell
in the homeostasis, as well as various pathologies, of the
central nervous system (CNS). It is now widely accepted
that clustered populations of reactive microglia are hall-
marks of Alzheimer’s disease (AD), and these brain cells
are likely to contribute to the mechanisms of neuronal
damage and cognitive loss [1]. Furthermore, activated
microglia have been associated with a variety of neuro-
degenerative diseases including AD, Parkinson’s disease
(PD) and amyotrophic lateral sclerosis (ALS) [1-3].
Since first described by Pio del Rio-Hortega in 1932
[4], microglia origins and functions in the CNS have
been extensively debated. The common consensus is
that microglia cells are of hematopoietic origin [5], how-
ever the specific cell lineage remains uncertain. The
colonization of CNS by microglia has been shown to
take place during embryonic development in rodents, at
a prenatal stage (E10 to E19) [6]. These findings support
the idea that there is heterogeneity of the microglial cell
origins in the CNS, with one population from myeloid/
mesenchymal origin (not necessarily derived from
monocytes) and a second population representing a de-
velopmental and transitory form of fetal macrophage
(possibly monocyte), which is an amoeboid microglial
cell as described in the postnatal brain of rodents [7].
Regardless of these cells origins, it is clear that they are
actively sensing and contributing to the changing micro-
cosm of the brain.
Microglia have activation states similar to that of
macrophages and exhibit functional plasticity during ac-
tivation states. The resting state, or ‘ramified’ state, is
relatively inactive or ‘quiescent’ but seems to perform
surveillance functions [8]. In addition to the resting
state, there are two functionally distinct activation states,
M1 and M2. The former is classically activated, for
* Correspondence: Kenneth.Hensley@utoledo.edu
1Department of Neurosciences, University of Toledo Medical Center, Toledo,
OH, USA
3Department of Pathology, University of Toledo Medical Center, Toledo,
OH, USA
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2012 Stansley et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Stansley et al. Journal of Neuroinflammation 2012, 9:115
http://www.jneuroinflammation.com/content/9/1/115
instance in response to IFN-γ or lipopolysaccharide
(LPS), and produces neuronal injury by secreting the
pro-inflammatory cytokines such as TNF-, IL-1β, and re-
active oxygen species/reactive nitrogen species (ROS/
NOS). In contrast, the amoeboid M2 state acts as an
anti-inflammatory by blocking the release of pro-
inflammatory cytokines, ingesting debris, promoting tis-
sue repair and releasing neurotrophic factors [9]. By
using in vitro culture techniques, researchers can find
ways to simulate many homeostatic or pathological con-
ditions by manipulating these states.
Microglia cultures have been described as early as the
1930s [10]; however, the use of cultures to study micro-
glia function did not occur until after a method for
obtaining and culturing large amounts of microglia was
developed and improved upon. The increased yield and
homogeneity of cells in culture allows for increased data
output in a shorter time compared to most in vivo
experiments. Also, these in vitro cultures present a bene-
ficial tool to study the activation state, releasable factors,
motility, and other crucial components that characterize
microglia, which cannot be sufficiently examined in vivo.
Presently there are many models of microglia and
microglia-like cell lines used to examine neuro-
inflammatory phenomena. These include primary micro-
glia cultures, and immortalized microglia cell cultures,
which are either retrovirus transformed or non-retrovirus
transformed. These culture models share similarities but
are also separated by crucial differences that must be
weighed when choosing an appropriate model for neuro-
degenerative research. The focus of this review is to com-
pare cell models with regard to origins, methods of
culturing specific cell lines, individual cell properties and
differences, and technical strengths and weaknesses. Fur-
thermore, given the prevalence of AD research involving
amyloid-β (β), the ability of each microglia type to react to
this molecule will be addressed.
Primary microglia cultures
Primary microglia cultures are very prevalent in neuro-
inflammatory research due to the similarities in pheno-
type to in vivo cells. These cells are most often derived
from the cortex of a rat or mouse before or early after
birth. In a process described by Giulian and Baker [8],
amoeboid microglia cells can be isolated from the mam-
malian brain and grown in culture. They show that by
using a specific process of adhesion and agitation of the
cultured glial cells, a purified culture of approximately
95% enriched microglia can be obtained [8] (Table 1).
This technique has been used extensively since its cre-
ation and, although sometimes slightly manipulated,
remains a popular method for cultivating in vitro micro-
glia. The advantages of using amoeboid microglia dir-
ectly from an animal are the functional characteristics
that these cells are endowed with, such as secretory pro-
ducts and cell surface markers, which closely resemble
endogenous cells.
When characterized, these cells were observed to be
homogeneously negative for glial fibrillary acidic protein
(GFAP, an astrocyte marker); galactocerebroside (GC an
oligodendrocyte marker); peroxidase activity (neutrophils);
and positive for non-specific esterases, all of which are indi-
cative of microglia cells [8]. When stimulated with LPS and
cytokines, primary microglia cultures have been shown to
release nitric oxide (•NO) via upregulation of inducible ni-
tric oxide synthase (iNOS, NOS-II) and superoxide (O2•)
anions via activation of NADPH oxidase (NOX) complexes
[11]. Furthermore, primary microglia secrete a host of other
anti- and pro-inflammatory factors when induced by stimu-
lating agents. Reactive oxygen species (ROS) and reactive
nitrogen species (RNS) are released upon activation, similar
to monocytes, macrophages and neutrophils [12].
Specifically relating to AD, microglial research has found
that the β oligomer, a known neurotoxin, may produce
more damage to neurons indirectly by activating microglia
[13]. Using in vitro cultures, subneurotoxic concentrations
of Aβ oligomer (5 to 50 nM) caused an activation of pri-
mary microglia, stimulating proliferation and •NO pro-
duction [13]. Furthermore, it has been shown that primary
microglia have the ability to phagocytose Aβ as a reaction
against Aβ accumulation [14]. This is an example of the
M2 activation state, which was discussed earlier. It has
also been shown that Aβ phagocytosis by primary micro-
glia can be inhibited by cytokines such as IL-1β, TNF-,
and IFN-γ, which most likely shifts the cells into the pro-
inflammatory M1 state [15].
The state of amoeboid microglia can change in vitro to
a ramified state (more quiescent), whereby the cells ex-
hibit elongation of processes, functional loss of ability to
phagocytose, and decreased proliferation. This transition
is accelerated by incubation with retinoic acid, an agent
known to increase cellular differentiation [8]. This
change in state is similar to the two different states seen
in vivo and provides yet another dynamic when studying
neuro-inflammatory processes in vitro.
The ability to measure these proteins and cell markers in
this cell model is beneficial; however, the extensive prepara-
tions needed for each experiment makes this model more
time consuming and perhaps less attractive as compared to
other microglia lines that have shorter prep-time, but main-
tain similar cell properties. One such way of obtaining cells
that have faster proliferation rates, have a more homoge-
neous population, and at a lower cost, is by genetically im-
mortalizing the primary microglia.
Retroviral immortalized microglia: BV2 and N9
With low cell number and the time consuming techni-
ques needed to cultivate primary microglia cultures,
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options were investigated to yield a large number of cells
quickly. Such immortalized cell lines can be generated
by infecting the cells with a retrovirus. Two commonly
used cell lines of this type are the BV2 and N9 microglia
cell lines which are derived from rat and mouse, respect-
ively. Both cell lines have been used extensively in re-
search related to neurodegenerative disorders.
After successfully immortalizing murine macrophages
from bone marrow via the v-raf/v-myc carrying retro-
virus (J2) [16], Blasi’s research group adapted this same
technique to form the BV2 microglia cells [17]. To de-
velop this line, microglia were first purified by adhesion/
agitation as described previously [8], then incubated
overnight with control or J2 virus containing superna-
tants in cell specific complete medium. After three to
four weeks of incubation, proliferating cells were
observed in infected cultures, where non-infected cul-
tures lost adherence and died [17].
The BV2 cells were assessed for microglia cell markers
and tested 90% positive for nonspecific esterase activity
and all lacked peroxidase activity. Furthermore, BV2
cells were positive for MAC-1 and MAC-2, but negative
for MAC-3 antigens. Also, similar to primary microglia,
they were negative for GFAP and GC antigens, markers
for astrocytes and oligodendrocytes [18], respectively.
Secretion of cytokines was assessed and it was found
that when stimulated with LPS, levels of IL-1 increased
dose dependently [17]. Also, given that these cells ex-
press phagocytic capabilities, it was demonstrated that
Aβ(1–42) fibrils can stimulate phagocytosis by microglia
in a time- and dose-dependent manner [19].
Even with the similarity to primary microglia, the cells
do contain oncogenes that render them in some ways
different from primary microglia, such as increased pro-
liferation and adhesion, and increased variance of
morphologies [20]. The validity of BV2 cells as a suffi-
cient substitute for primary microglia has been debated,
and as a result, a few studies comparing different micro-
glia lines emerged. One such study was conducted by
Horvath et al. [20], who compared primary rat microglia
to the BV2 line with regard to activation markers, motil-
ity and releasable factors, such as •NO and cytokines. It
was observed that the primary microglia and BV2 cells
both express Iba-1, a microglia activation marker. Fur-
thermore, upon LPS stimulation, BV2 cells secreted
lesser but still substantial amounts of •NO compared to
primary microglia [20].
The major idea that BV2 immortalized cells have simi-
lar functions as primary microglia, but not to the same
extent, was further examined by Henn et al. [21]. This
group examined the BV2 cells as an appropriate alterna-
tive to the primary cultures. They found that in response
to LPS, 90% of genes induced by the BV2 cells were also
induced by primary microglia; however, the up-
regulation of genes in the BV2 was far less pronounced
than in primary microglia [21].
With the BV2 cell line, there appears to be a trade-off
of magnitude of stimulatory response, with preparation
time and technical feasibility between experiments. An-
other popular retroviral-immortalized cell line, the N9
microglia line, has also been used in cultures in an at-
tempt to expedite bench work, while maintaining the
crucial properties of in vivo microglia.
The N9 microglia is derived from mouse brain and
shares many phenotypical characteristics with primary
mouse microglia. This is exemplified by a number of
studies including one by Hickman et al. [22]. Hickman’s
group examined Aβ peptide clearance and receptor
regulation of microglia by performing some experiments
with the N9 cell line. They discovered that when the
N9s were incubated with TNF- there were decreases in
the expression of scavenger receptor A and CD36 and
also reductions in Aβ uptake, supporting the results they
obtained from primary mouse microglia. There is evi-
dence that this cell line shares similarities with the pri-
mary microglia; however, they are genetically modified,
which leads to increased proliferation and adherence.
The N9 microglia cells were developed by immortaliz-
ing primary microglia cells with the v-myc or v-mil
oncogenes of the avian retrovirus MH2 [23]. The clones
derived from this process were characterized as exhibit-
ing nonspecific esterase activity and testing positive for
microglia cell surface markers FcR, Mac-1 and F4/80.
Furthermore, they are negative for GFAP, A2B5, and
Table 1 Amoeboid microglia isolation procedure
Step Manipulation Time
1. Dissection and mechanical dissociation of cerebral tissue from newborn rat 1 hour
2. Incubate in flask with defined medium, 37 °C 1 day
3. Agitation by rotary shaker, 180 rpm, 37 °C 15 hours
4. Adhesion incubation in flask, 37 °C 1 to 3 hours
5. Agitation by hand, 20 °C 2 to5 minutes
6. Adhesion incubation in flask, 37 °C 1 to 3 hours
7. Agitation by hand, 20 °C 2 to 5 minutes
The table is adapted from Guilian and Baker, 1986 [8]. The table describes a common procedure for obtaining primary microglial cells.
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Gal-C. The microglia can also phagocytose opsonized
sheep red blood cells (SRBCs) and readily produce cyto-
kines. Upon stimulation with LPS, these cells produce
IL-6, TNF- and IL-1 [23].
It has also been demonstrated that the N9 microglia
line possesses purinergic receptors including the P2Y
and P2Z subtypes, which are ATP sensitive. The P2Z re-
ceptor has been shown to be involved in IL-1β release in
response to ATP stimulation [24]. In that study, the P2Z
receptor was modulated by growing N9 cells in the pres-
ence of a high concentration of ATP, which selected for
ATP-resistant clones. By comparing amounts of IL-1β
released upon ATP stimulation from the cells with func-
tional P2Z receptors and the ATP-resistant clones, it
was concluded that the P2Z receptor was responsible for
IL-1β release after ATP stimulation.
Establishing these purinergic receptor qualities in this cell
line also indicates a similar Ca2+ signaling profile to that of
primary microglia. Experiments such as these lend insight
into the ability to passage immortalized microglia cells in
the presence of trophic factors to select for a desired
phenotype or modulate protein expression patterns.
These immortalized cell lines have been used to demon-
strate the ability of microglia to change state and assume
different roles in the AD brain, specifically in response to
Aβ. The BV2 microglia have been shown to uptake Aβ by
phagocytosis, a process that was increased dose depend-
ently by specific neuropeptide incubation. Furthermore, the
study found that the degradation of Aβ was unaffected. The
intracellular enzyme level of neprilysin, which is thought to
degrade Aβ, was lower after Aβ, suggesting that Aβ could
negatively regulate the levels of neprilysin [25]. In
agreement with research using primary microglia, the pro-
inflammatory genes including INOS, COX-2, TNF- and IL-
1β were up-regulated [26]. Apart from gene levels, oligo-
meric Aβ has been shown to increase ROS and nitric oxide
in the BV2 cells. The N9 microglia have also been shown to
up-regulate the pro-inflammatory genes, similarly to the
BV2, including INOS, COX-2,TNF- and IL-1β [25]. Further-
more, Fu et al. reported a Mac-1/Complement component
3 mediated phagocytosis of fibrillar Aβ by N9 microglia
[27].
This ability to employ the cell model to help answer
specific inflammatory research questions can be valu-
able. Along the same line, it has often been argued that
it is also important to use a cell line that is appropriate
for the model system being used,(that is, N9 for the
mouse model, BV2 for the rat model, and so on.). So,
the human model, which is arguably one of the most im-
portant model systems, has its own cell line as well.
Human immortalized microglia: HMO6
Human microglia systems are used in neuroscience re-
search; however, it is more difficult to obtain these cells
because they have to be derived from human embryos,
which can be difficult to access due to the ethical and
legal issues. Nagai’s group sought to circumvent this
issue by creating an immortalized human microglia cell
line, the HMO6 [28]. This cell line was established by
using primary human embryonic microglia cultures. The
cells were stimulated to proliferate by incubation with
8 μg/mL granulocyte-macrophage-colony-stimulating-
factor in medium for seven to 12 days and then infected
with the PASK 1.2 retroviral vector, which transcribed
the v-myc oncogene. As a culture, the doubling time for
these cells was quite fast, at 34.5 hours. The cells also
adhered to glass or plastic and maintained the ability to
phagocytose latex beads. Furthermore, HMO6 cells were
positive for staining with Ricinus communis agglutinin
(RCA) and CD11b (MAC-1) and express transcripts for
purinergic receptors, confirming a microglia phenotype.
Nagai’s group also performed RT-PCR analysis and
showed gene expression of IL-1β, IL-6, IL-8, IL-10, IL-
12, IL-15 and TNF-.
The characteristics of HMO6 cells make them appro-
priate for investigating pro-inflammatory processes in
AD like pathology. Specifically, HMO6 cells have also
been shown to express TNF- and IL-8. Following a 48-
hour incubation with β peptide (25–35) or LPS. HMO6
cells increased gene expression and protein production
of IL-8 and TNF- [28]. Furthermore, in a study in 2008,
it was found that when HMO6 cells were treated with
Aβ(1–42) or LPS the cells expressed high levels of the
protein albumin, which has been implicated as a role
player in the pathogenesis of AD [29].
These human-derived cell lines are rarely used based
on the fact that it is difficult to obtain a primary culture
to transfect. More research is conducted in non-human
animals and, thus, murine microglia cultures are more
commonly used.
Spontaneously immortalized: EOC and HAPI
There are a few cell lines that offer highly proliferating
microglia which are not genetically modified. Some
common lines include the colony stimulating factor-1
dependant EOC cells [30] and also the Highly Aggres-
sively Proliferating Immortalized (HAPI) cell line [31].
Similar to primary microglia, these cells possess the
ability to secrete many cytokines and reactive species, in-
cluding •NO. The •NO production of microglia is an
important factor to consider in the pathogenesis of AD
because it has been shown that Aβ(1–42) can cause sig-
nificant production of NO2, a stable metabolite of •NO
[32]. Using the EOC-20 line, Hensley et al. [33] found
that stimulation of microglia cells by 20 ng/mL recom-
binant TNF- causes a large NO2
- production, as mea-
sured by the Greiss reaction. It was also shown that the
stimulated NO2
- production of EOC-20 cells can be
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inhibited by a CNS metabolite called lanthionine keti-
mine (LK) as well as its synthetic ether derivative, LKE
[33]. The modulation of •NO production using these
microglia can have important implications for future re-
search in neurodegenerative disorders where •NO is
known to be associated with pathological conditions.
Mouse-derived EOC cells are available from American
Type Culture Collection (ATTC) in subtypes EOC-2, EOC-
13.31, and EOC-20. The numbers following EOC are desig-
nated by the colonies they were originally derived from
within the first culture by Walker et al. [30]. The major dif-
ference is that the EOC-2, unlike EOC-13.31 and EOC-20,
does not express major histocompatibility complex class II
(MHCII). Furthermore, the MHCII is up-regulated by re-
combinant IFN-γ in EOC-20 cells but not in EOC-13.31.
These differences are often considered when using cell lines
to investigate differential activation by cytokines in neuro-
degenerative research. Specifically, Hensley’s research group
noted a TNF--induced NO2
- production in EOC-20 cells,
which was potentiated by co-incubation with TNF- plus
IFN-γ or IL-6 [34]. Furthermore, in recent experiments the
Hensley laboratory has found that the •NO production and
up-regulation of iNOS is dependent on both TNF- and
IFN-γ in combination (Figure 1). This change in cytokine
activation may be attributed to cell strain evolution during
repeated passaging and freeze-thaw storage procedures or
unspecified laboratory level differences. This situation also
highlights the ability of immortalized cells to change
phenotypically over time. These cells are easily cultured;
however, they do require colony-stimulating factor-1 (CSF-
1). CSF-1 can be obtained from a separate cell line, the
bone marrow derived LADMAC (ATCCW CRL-2420)
which produce this factor. So in order to culture EOC cells,
LADMAC cells are required to complete the EOC condi-
tioned medium. The similarly spontaneously immortalized
cell line, the HAPI microglia, is derived from rat and is not
dependent on a specific growth factor to maintain
immortalization.
The HAPI cell line was first recognized to be spontan-
eously immortalized by Cheepsunthorn et al. and was
observed to be highly proliferating within an enriched
primary microglia culture [31]. One day after primary
microglia purification by the ‘shake off ’ method
described by Giulian and Baker [8], cells were harvested
and cultured in 10% fetal bovine serum. These cells pos-
sess the ability to phagocytose, as well as test positive for
OX42, which recognizes complement 3 receptors, indi-
cating a phenotype typical of microglia. Furthermore,
the cells were negative for A2B5 and GFAP.
To further characterize this cell line, Cheepsunthorn
et al. [31] used RT-PCR analysis to discover that treatment
with LPS up regulates proinflammatory cytokines such as
TNF- and iNOS mRNA in HAPI cells. In addition to this,
it was also found that in response to LPS, these cells
produce significant quantities of •NO and TNF- in the
spent culture medium. Furthermore, methamphetamine
stimulation produces several cytotoxic factors including IL-
1β, IL-6, TNF-, and ROS/RNS [35]. This methampheta-
mine activation of microglia which results in cytokine and
•NO release is reduced by melatonin pretreatment which
also increased cell viability in cultures [35].
Similar to inflammogen stimulants such as LPS and
methamphetamine, Aβ also has the ability to activate
EOC microglia. When EOC cells were exposed to
Aβ(24–35) and incubated with carboxy-H2DCFA,
Manzano-Leon et al. found an increase in fluorescence
after 24 hours, indicating an increase in production of
ROS [36]. This rise in ROS was suggested to alter the
protein β-adaptin, a molecule needed to organize the
endocytic machinery in microglia, and contribute to the
Figure 1 •NO production in EOC-20 cells. A, EOC-20 microglia
stimulated only with TNF + IFNγ in combination. Each error bar
represents mean± SEM from six wells of a typical experiment. B, LKE
inhibits cytokine-stimulated •NO production in EOC-20 microglia
challenged with 40 ηg/mL TNF+ 40 ng/mL IFNγ. Each point
represents mean± SEM from four wells of a typical experiment. SEM,
standard error of the mean.
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lack of Aβ clearance in AD. In HAPI cells, Aβ(1–42)
induces serine racemase, the enzyme that converts L-
serine to D-serine. D-Serine then acts on neuronal
NMDA receptors as a signaling molecule [37]. Although
there have been some studies done using EOC and
HAPI microglia to examine Aβ effects, the amount of
published research is relatively small in comparison with
primary cultures or other immortalized cell lines.
Future directions of microglia culture experimentation
In any reductionist approach, experiments that lack the
entire brain milieu will leave gaps in translatability to
in vivo situations and thereby be subject to scrutiny.
However, by minimizing surrounding variables, it allows
researchers to study functional aspects of microglia un-
encumbered by those surrounding factors that may
make it difficult to tease apart microglia function from
other cells in proximity. A variety of microglial cell lines
are now used routinely for research purposes, in
addition to primary microglia. Table 2 summarizes the
principal characteristics of the common microglial cul-
ture systems described in this review, with special atten-
tion to their sensitivity towards Alzheimer’s disease-
associated amyloid beta-peptides.
One way to add another dynamic to microglia culture
systems, which can help assess microglia interaction with
other cell types, is co-cultures. Several studies have been
published in which microglia are cultured with neurons
and/or astrocytes to study the interaction of these cells.
This allows for the in vitro environment to be controlled as
far as temperature, medium content and other factors. La-
boratories studying neurodegenerative diseases with neuron
cultures can benefit from these co-cultures as well, because
microglia have been shown to have many interactions with
the micro-environment.
It is known that in AD high concentrations of Aβ(1–40)
or Aβ(1–42) do not cause neuronal damage if microglia are
not present [1]. So, by utilizing co-culture methods, Li et al.
activated microglia with Aβ precursor protein or LPS and
then placed the microglia with neocortical neurons [38].
They found that in conditions where activated microglia
were present, there was a significant increase in phosphor-
ylation of neuronal tau and a decline in synaptophysin
levels, similar to tangles found in the AD. Furthermore, in
regards to microglia activation, co-cultures of microglia
with motor neurons that were treated with IL-4, showed a
suppression of the M1 microglial activation, which reduced
the release of ROS and improved motor neuron survival
[39]. These situations highlight some of the ways in which
microglia co-cultures can be very useful in neurodegenera-
tion research.
Microglia cell lines certainly do not come without
faults. One problem may be with selection of certain cell
characteristics that differ between laboratories due to
medium or culturing conditions [19]. This can lead to
similar treatment conditions yielding far different cell
responses. One instance of this was the study of
TNF- expression and release in HAPI microglia by
Cheepsunthorn et al., [31] and Horvath et al. [18]. While
characterizing these cells, both groups stimulated HAPI
microglia with LPS, and Cheepsunthorn et al. [31] found
an increase in TNF- expression and release. Similarly,
Horvath et al. [18] found increased expression at 24 and
48 hours following LPS treatment; however, there was no
release of TNF- into the medium at either time point.
Horvath et al. [18] reasoned that the discrepancy may
have occurred due to genetic drift of the cell line or pos-
sibly technical differences in the experimental preparation.
This is an example of how cell lines may react differently
in different hands due to many different factors. It also
sheds light on the immortalized cell lines ability to genet-
ically drift or select for certain phenotypes, as they are pas-
saged many times over. To control for this, culture
techniques and methods must become more cohesive and
standardized within the research community and supply
companies.
The biological functioning of microglia in many brain
pathologies, especially AD, has led to the development
of several cell lines. While primary microglia cultures
tend to be the closest to in vivo microglia, they are more
tedious and technically time consuming to prepare. Also,
the populations may not be completely homogeneous
for microglia because astrocytes or oligodendrocytes
Table 2 Microglia properties by cell line
Primary
Microglia
BV2 N9 HMO6 EOC HAPI
MAC-1 + + + + + +
LPS stimulation + + + + + +
lL-1β release + - + - N/A +
TNF- release (Following LPS) + + + + N/A +
Phagocytosis + + + + + +
Peroxidase - - - - - -
Non-specific esterase + + + + + +
GFAP - - - - - -
GC - - - - - -
•NO production + + + - + +
Aβ induced lL-β + + + - N/A N/A
Aβ induced TNF- + + + + N/A N/A
Aβ phagocytosis + + + N/A N/A N/A
Number of articles in Pub Meda 302 142 91 8 18 19
The table represents properties of individual cell lines as reported by citations
in the PubMed Database (http://www.ncbi.nlm.nih.gov/). (+) Positive for trait,
(−) negative for trait. aSpecific PubMed search term ‘primary microglial cell
culture’ (from year 2000 to present; includes both studies of endogenous
microglia as well as primary cultures of microglial isolates). Aβ, amyloid β; GC,
galactocerebroside; GFAP, glial fibrillary acidic protein; LPS, lipopolysaccharide.
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may also remain in the culture. Conversely, immorta-
lized cell lines tend to be a high throughput model for
experimentation and are completely homogeneous
throughout the culture. This comes at the cost of having
an inflammatory response that is not identical to pri-
mary cultures. Also, the immortalized cells are subject
to genetic drift and morphology changes. Taken together,
these microglia cell lines share common strengths, with
the goal of all cell lines being to provide the best tool for
the study of microglia-related phenomena, and to help
understand brain diseases.
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